Keytruda meets PFS primary endpoint in phase III KEYNOTE-204

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III KEYNOTE-204 trial evaluating Keytruda in adult patients with relapsed or refractory classical Hodgkin lymphoma met one of its dual primary endpoints of progression-free survival.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login